Instead, responses are mediated by Hrh1 receptor sensitization of TRPV1 signaling, suggesting that similar to “standard” IBS12, Hrh1 antagonism may represent an interesting new target for treatment of PI-IBS. Here, TRPV1 is linked to irritable bowel syndrome.